CD19 and non-Hodgkin lymphoma: Hirayama et al. [36] launched a phase IB trial in patients with R/R CD19-positive NHL-B to evaluate JCAR014, an autologous anti-CD19 CAR-T therapy, in combination with durvalumab (with dose escalation 21–28 days after or 1 day before JCAR014 infusion).